Merck Kgaa Unsp ADR (MKGAY) 54.9600 $MKGAY
Rectal Cancer - Pipeline Review, H1 2014
M2 - 2 hrs 33 mins ago
Research and Markets (http://www.researchandmarkets.com/research/d94ppq/rectal_cancer) has announced the addition of the "Rectal Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Rectal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rectal Cancer and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Rectal Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Rectal Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Rectal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Rectal Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned: - AbbVie Inc. - Celltrion, Inc. - Eisai Co., Ltd. - GenVec, Inc. - GlaxoSmithKline plc - Hanwha Chemical Corporation - Isofol Medical AB - Merck & Co., Inc. - Merck KGaA - Nanobiotix - Peregrine Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. For more information visit http://www.researchandmarkets.com/research/d9...tal_cancer
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2014: 33 Companies and 48 Drugs Profiled
M2 - Thu May 08, 4:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/grpwf5/metastatic) has announced the addition of the "Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline Companies Involved: - ATLAB Pharma SAS - AbbVie Inc. - Active Biotech AB - Astellas Pharma Inc. - AstraZeneca PLC - Bavarian Nordic A/S - Bellicum Pharmaceuticals, Inc. - Bind Therapeutics, Inc. - Bostwick Laboratories, Inc. - CellCentric Ltd. - CureVac GmbH - DexTech Medical AB - Eli Lilly and Company - Emergent BioSolutions Inc. - Exelixis, Inc. - GTx, Inc. - GenSpera, Inc. - Genentech, Inc. - Medivation, Inc. - Merck KGaA - Millennium Pharmaceuticals, Inc. - NewLink Genetics Corporation - Novartis AG - Oncolytics Biotech Inc. - Oncothyreon Inc. - Onyx Pharmaceuticals, Inc. - Progenics Pharmaceuticals, Inc. - Sotio a.s. - Supratek Pharma Inc. - Synta Pharmaceuticals Corp. Drug Profiles: - enzalutamide - orteronel - custirsen sodium - tasquinimod - enzalutamide - cabozantinib (s)-malate - Prostvac - DCVAC/PCa - patupilone - DI-17-E-6 - olaratumab - navitoclax - vandetanib - PSMA ADC - GTx-758 - linsitinib - olaparib - panobinostat - carfilzomib - ganetespib - pelareorep - PX-866 - CV-9103 - G-202 - docetaxel targeted nanoparticles - buparlisib hydrochloride - NLG-8189 - Adenovirus/PSA Vaccine - TL-118 - CV-9104 For more information visit http://www.researchandmarkets.com/research/grpwf5/metastatic
Polycystic Ovarian Syndrome - Pipeline Review, H1 2014: 6 Company Profiles and 11 Drugs Profiled
M2 - Thu May 08, 4:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/43d5b3/polycystic) has announced the addition of the "Polycystic Ovarian Syndrome - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Polycystic Ovarian Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Polycystic Ovarian Syndrome and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Polycystic Ovarian Syndrome - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Polycystic Ovarian Syndrome and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Polycystic Ovarian Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Polycystic Ovarian Syndrome pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved: - AstraZeneca PLC - Euroscreen S.A. - Neurocrine Biosciences, Inc. - Merck KGaA - EffRx Pharmaceuticals S.A. - Crinetics Pharmaceuticals, Inc. Drug Profiles: - choriogonadotropin alfa - doxycycline - AZD-4901 - ESN-364 - GnRH Antagonists - metformin hydrochloride - Drugs to Inhibit GnRH Receptor for Dermatology, Hormonal Disorders, Non Malignant Disorders, Oncology and Women Health - Kisspeptin Peptide Antagonists - Metabolic Syndrome Program - KISS-1R Antagonist For Polycystic Ovarian Syndrome - Drugs to Inhibit PAI-1 for Thromboembolic Disease, PCOS and Alopecia For more information visit http://www.researchandmarkets.com/research/43d5b3/polycystic
Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H1 2014: 79 Companies Profiled
M2 - Wed May 07, 12:21PM CDT
Research and Markets (http://www.researchandmarkets.com/research/2d32kc/type_1_diabetes) has announced the addition of the "Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Type 1 Diabetes (Juvenile Diabetes), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Type 1 Diabetes (Juvenile Diabetes) and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - Alcon, Inc. - Johnson & Johnson - Boehringer Ingelheim GmbH - Osiris Therapeutics, Inc. - Sanofi - AstraZeneca PLC - Eli Lilly and Company - Inovio Pharmaceuticals, Inc. - MedImmune, LLC - Daiichi Sankyo Company, Limited - Merck & Co., Inc. - AbGenomics International, Inc. - Novo Nordisk A/S - Generex Biotechnology Corporation - BioLineRx, Ltd. - Kissei Pharmaceutical Co., Ltd. - Pfizer Inc. - Cell Therapeutics, Inc. - Hadasit Medical Research Services & Development Ltd - Biodel Inc. - MannKind Corporation - Halozyme Therapeutics, Inc. - Merck KGaA - Evotec AG - Karo Bio AB - Ligand Pharmaceuticals, Inc. - Opexa Therapeutics, Inc. - Compugen Ltd. - Oramed Pharmaceuticals, Inc. - Lexicon Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/2d...1_diabetes
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H1 2014: 23 Companies and 33 Drugs Profiled
M2 - Wed May 07, 12:10PM CDT
Research and Markets (http://www.researchandmarkets.com/research/p7dbhq/relapsing) has announced the addition of the "Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS) and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Companies Involved in Therapeutics Development - AbbVie Inc. - Actelion Ltd - Allozyne, Inc. - Amarna Therapeutics B.V. - Biogen Idec Inc. - Cognosci, Inc. - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. - Genmab A/S - GlaxoSmithKline plc - MedImmune, LLC - Merck KGaA - Mitsubishi Tanabe Pharma Corporation - Neurotec Pharma SL - Novartis AG - Nuron Biotech, Inc. - Opexa Therapeutics, Inc. - Receptos, Inc. - RedHill Biopharma Ltd. - Synthetic Biologics, Inc. - Teva Pharmaceutical Industries Limited - Trophos SA - XenoPort, Inc. Drug Profiles: - laquinimod sodium - dimethyl fumarate - laquinimod sodium - fingolimod hydrochloride - ocrelizumab - interferon beta-1b - daclizumab - RPC-1063 - Epigallocatechin Gallate - GSK-239512 - siponimod - tabalumab - firategrast - ponesimod - plovamer acetate - estriol - imilecleucel-t - olesoxime - ofatumumab - RNS-60 - (rifabutin clarithromycin clofazimine) - diazoxide - MT-1303 - Boswellic Acids - VAY-736 - MEDI-551 - interferon beta-1b pegylated - XP-23829 - Pegylated Interferon-Beta-1b - COG-133 For more information visit http://www.researchandmarkets.com/research/p7dbhq/relapsing
Women Infertility - Pipeline Review, H1 2014: 17 Company and 34 Drug Profiles
M2 - Wed May 07, 8:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wfm23g/women_infertility) has announced the addition of the "Women Infertility - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Women Infertility, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Women Infertility and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by our team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Involved in Therapeutics Development: - ASKA Pharmaceutical Co., Ltd. - Access Pharmaceuticals, Inc. - Actavis plc - AlphaMab Co., Ltd - Dong-A Socio Holdings Co Ltd - Ferring Pharmaceuticals, Inc. - Finox AG - Glycotope GmbH - Hanmi Pharmaceuticals, Co. Ltd. - IBSA Institut Biochimique SA - Isifer AB - Merck & Co., Inc. - Merck KGaA - Pantec Biosolutions AG - PregLem SA - Reliance Life Sciences Pvt. Ltd. - Teva Pharmaceutical Industries Limited - Trophogen, Inc. - Zydus Cadila Healthcare Limited Drug Profiles - corifollitropin alfa - follitropin alfa biosimilar - DR-2011 - choriogonadotropin alfa biosimilar - progesterone - RTPR-013 - follitropin alfa biosimilar - follitropin alfa biosimilar - follitropin delta - Isifera - FSH-GEX - menotropins - nimodipine - kisspeptin - filgrastim - triptorelin - progesterone Vaginal Gel Second Generation - AKP-501 - PGL-1001 - Prod-4 - Oral Fertility Drugs - HM-12160B - Follicle Stimulating Hormone Analog - Luteinizing Hormone Analog - KN-015 - Drugs to Inhibit GnRH Receptor for Dermatology, Hormonal Disorders, Non Malignant Disorders, Oncology and Women Health - follitropin alfa biosimilar - choriogonadotropin alfa biosimilar - Drugs for Female Infertility - FSH Agonist for Infertility For more information visit http://www.researchandmarkets.com/research/wf...nfertility
Bayer to buy Merck consumer business for $14.2B
By LINDA A. JOHNSON - AP - Tue May 06, 4:07PM CDT
TRENTON, N.J. (AP) — Germany's Bayer plans to buy U.S.-based Merck & Co.'s consumer health business, creating a combined medicine cabinet of household names from Bayer's aspirin to Merck's Claritin allergy pills.
Merck Wins Chinese Approval for AZ Electronics Takeover
at The Street - Thu May 01, 8:24AM CDT
China's Ministry of Commerce imposes conditions on the $3.1 billion deal.
Merck KGaA: Form 8 (DD) - AZ Electronic Materials S.A.
Marketwire - Wed Apr 30, 5:31AM CDT
Merck KGaA (FRANKFURT: MRK)
Global Cell Analysis Market 2014-2019: Instruments (Flow Cytometer, Microscope, Microfluidics, QPCR) & Application (Cell ID, Cell Viability, Cell Proliferation, Cytology, Signal Transduction, Single Cell)
M2 - Mon Apr 28, 9:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8bcf6h/cell_analysis) has announced the addition of the "Global Cell Analysis Market 2014-2019: Instruments (Flow Cytometer, Microscope, Microfluidics, QPCR), Consumables & Application (Cell Identification, Cell Viability, Cell Proliferation, Cytology, Signal Transduction, Single Cell Analysis)" report to their offering. In the recent years, the adoption of Cell Analysis for Cell identification, single cell analysis, cell proliferation, cell signaling, cell viability, cell signaling/transduction pathway, cell counting and quality control, cell structure study, and cell interaction, has increased. The market is broadly classified based on products, applications, end users, and geographies. The products market is further divided into instruments and consumables. The instruments market is sub-divided into cell counting instruments, microscopy, flow cytometry, high content screening, spectrophotometery, microfluidics, qRT-PCR, and cell microarrays. The consumables market is further segmented into reagents and assay kits, microplates, and other consumables. The applications market includes cell identification, cell interaction, cell viability, cell proliferation, cell structure studies, cell signaling pathway/signal transduction, cell counting and quality control, target identification, and validation and single cell analysis. Cell identification has its application in the identification of blood cells on the basis of their size and other morphological features such as presence or absence of nucleus in the cell and shape of nucleus. Cell identification is also used in tumor cell identification with the help of Raman spectroscopy and microfluidics. In target identification, HCS is used to identify novel targets through the screening of cellular pathways. HCS can also provide more accurate information about drug toxicity and mode of actions, which helps in further decision making and in driving the progress of drug discovery. Cell signalling pathways are used for the analysis of signalling pathways in drug discovery and therapeutic development, to differentiate drug resistant patterns in cancerous cells. The major factors driving the growth of the market are the rising incidence of cancer, corporate and government funding for cell-based research activities, rising incidence of chronic and infectious diseases, introduction of enhanced informatics solutions and improvements in image analysis products, and growing healthcare and medical spending. Moreover, the adoption of cell analysis for cell identification and cell signaling pathways/signal transduction pathways is the key growth opportunity in this market. Scope Instruments - Flow Cytometer - Microscope - Microfluidics - QPCR Consumables Application - Cell Identification - Cell Viability - Cell Proliferation - Cytology - Signal Transduction - Single Cell Analysis The report provides insights on the following pointers: - Market Penetration: Comprehensive information on the product portfolios and services offered by the top players in the cell analysis market. The report analyzes the cell analysis market by application across geographies. - Product Development/Innovation: Detailed insights on research and development activities and new product launches in the cell analysis market. - Market Development: Comprehensive information about the lucrative emerging markets. The report analyzes promising applications of the cell analysis market by product across geographies. - Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the cell analysis market. - Competitive Assessment: In-depth assessment of strategies, products and services, and distribution networks in the cell analysis market. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Market Overview 4 Global Cell Analysis Market, By Product Type 5 Products Market 6 Global Cell Analysis Market, By End Users 7 Geographic Analysis 8 Competitive Landscape 9 Company Profiles - Agilent Technologies, Inc. - Beckton, Dickinson and Company - Danaher Corporation - GE Healthcare - Merck KGAA - Olympus Corpopration - Perkinelmer, Inc. - Promega Corporation - Sigma-Aldrich Corporation - Thermo Fisher Scientific, Inc. For more information visit http://www.researchandmarkets.com/research/8b...l_analysis
Global Leishmaniasis (Kala-Azar) Therapeutics Pipeline Review 2014 - Analysis of 10 Companies & 30 Drug Profiles
M2 - Mon Apr 28, 5:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pr5bk6/leishmaniasis) has announced the addition of the "Leishmaniasis (Kala-Azar) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Leishmaniasis (Kala-Azar), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Leishmaniasis (Kala-Azar) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Leishmaniasis (Kala-Azar) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Leishmaniasis (Kala-Azar) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Leishmaniasis (Kala-Azar) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Involved in Therapeutics Development - Sanofi - Takeda Pharmaceutical Company Limited - Photopharmica Limited - Merck KGaA - iCo Therapeutics Inc. - Mologen AG - Advinus Therapeutics Ltd. - Dafra Pharma International Ltd. - aRigen Pharmaceuticals, Inc. - PolyTherics Limited Drug Profiles - pentoxifylline - fexinidazole - LEISH-F3 Vaccine - amphotericin B - MGN-1331 - Oleylphosphocholine - AS-605240 - Vaccine For Leishmania - amphotericin B NanoDisk - Small Molecules for Infectious Diseases - Small Molecule For Cutaneous Leishmaniasis - Small Molecule for Leishmaniasis - S-010269 - Compound-2d - VL-2098 - Compound-26g - pegylated amphotericin B - amphotericin b - Small Molecules For Leishmaniasis And Malaria - Isoxazole Containing Heteroretinoid And Amide Derivatives - Drug for Parasitic Diseases - Neglected Disease Program 2 - Small Molecules for Leishmaniasis and Oncology - methoxycoronaridine - Small Molecules to Inhibit HDAC for Oncology and Infectious Diseases - CDRI-99/288 - Nitroimidazole Backup Compound - Drug to Inhibit PDE for Leishmaniasis and Trypanosomiasis - Transfollicular Leishmaniasis Nanovaccine - ARA-03 For more information visit http://www.researchandmarkets.com/research/pr...shmaniasis
EMD Serono Presents New Data on Rebif® (interferon beta-1a) and Advancing MS Pipeline at AAN Annual Meeting
PR Newswire - Fri Apr 25, 8:00AM CDT
EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, announced today that new data from the company's multiple sclerosis (MS) portfolio will be presented at the American Academy of Neurology's 66th Annual Meeting, taking place from April 26 - May 3, in Philadelphia, PA.
BlackBerry CEO May Consider Exiting Handset Business; Celgene Corporation Favored over Natco in Pre-trial
ACCESSWIRE - Wed Apr 09, 11:43PM CDT
Merck & Co. Inc. (NYSE: MRK) - For an in-depth report on Merck & Co. Inc. follow: www.BullTrends.com/stockquote/MRK
Oncothyreon Announces Merck KGaA, Darmstadt, Germany, Initiation of Phase 3 START2 Study with Tecemotide in Stage III Non-Small Cell Lung Cancer
PR Newswire - Mon Apr 07, 5:00AM CDT
Oncothyreon Inc. (NASDAQ: ONTY) today announced that Merck KGaA, Darmstadt, Germany, has initiated the international Phase 3 START2 study, which is designed to assess the efficacy and safety of the investigational MUC1 antigen-specific cancer immunotherapy tecemotide (also known as L-BLP25) in patients with unresectable, locally advanced Stage III non-small cell lung cancer (NSCLC). Merck KGaA, Darmstadt, Germany, is developing tecemotide under a license agreement with Oncothyreon.
EMD Serono Announces Initiation of Phase III START2 Study with Tecemotide in Stage III Non-Small Cell Lung Cancer
CNW Group - Mon Apr 07, 1:20AM CDT
EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, today announced the initiation of the international Phase III START2 study, which is designed to assess the efficacy and safety of its investigational MUC1 antigen-specific cancer immunotherapy tecemotide (also known as L-BLP25) in patients with unresectable, locally advanced Stage III non-small cell lung cancer (NSCLC).
Rectal Cancer - Pipeline Review, H1 2014
M2 - 2 hrs 33 mins ago
Research and Markets (http://www.researchandmarkets.com/research/d94ppq/rectal_cancer) has announced the addition of the "Rectal Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Rectal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rectal Cancer and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Rectal Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Rectal Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Rectal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Rectal Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned: - AbbVie Inc. - Celltrion, Inc. - Eisai Co., Ltd. - GenVec, Inc. - GlaxoSmithKline plc - Hanwha Chemical Corporation - Isofol Medical AB - Merck & Co., Inc. - Merck KGaA - Nanobiotix - Peregrine Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. For more information visit http://www.researchandmarkets.com/research/d9...tal_cancer
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2014: 33 Companies and 48 Drugs Profiled
M2 - Thu May 08, 4:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/grpwf5/metastatic) has announced the addition of the "Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline Companies Involved: - ATLAB Pharma SAS - AbbVie Inc. - Active Biotech AB - Astellas Pharma Inc. - AstraZeneca PLC - Bavarian Nordic A/S - Bellicum Pharmaceuticals, Inc. - Bind Therapeutics, Inc. - Bostwick Laboratories, Inc. - CellCentric Ltd. - CureVac GmbH - DexTech Medical AB - Eli Lilly and Company - Emergent BioSolutions Inc. - Exelixis, Inc. - GTx, Inc. - GenSpera, Inc. - Genentech, Inc. - Medivation, Inc. - Merck KGaA - Millennium Pharmaceuticals, Inc. - NewLink Genetics Corporation - Novartis AG - Oncolytics Biotech Inc. - Oncothyreon Inc. - Onyx Pharmaceuticals, Inc. - Progenics Pharmaceuticals, Inc. - Sotio a.s. - Supratek Pharma Inc. - Synta Pharmaceuticals Corp. Drug Profiles: - enzalutamide - orteronel - custirsen sodium - tasquinimod - enzalutamide - cabozantinib (s)-malate - Prostvac - DCVAC/PCa - patupilone - DI-17-E-6 - olaratumab - navitoclax - vandetanib - PSMA ADC - GTx-758 - linsitinib - olaparib - panobinostat - carfilzomib - ganetespib - pelareorep - PX-866 - CV-9103 - G-202 - docetaxel targeted nanoparticles - buparlisib hydrochloride - NLG-8189 - Adenovirus/PSA Vaccine - TL-118 - CV-9104 For more information visit http://www.researchandmarkets.com/research/grpwf5/metastatic
Polycystic Ovarian Syndrome - Pipeline Review, H1 2014: 6 Company Profiles and 11 Drugs Profiled
M2 - Thu May 08, 4:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/43d5b3/polycystic) has announced the addition of the "Polycystic Ovarian Syndrome - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Polycystic Ovarian Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Polycystic Ovarian Syndrome and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Polycystic Ovarian Syndrome - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Polycystic Ovarian Syndrome and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Polycystic Ovarian Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Polycystic Ovarian Syndrome pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved: - AstraZeneca PLC - Euroscreen S.A. - Neurocrine Biosciences, Inc. - Merck KGaA - EffRx Pharmaceuticals S.A. - Crinetics Pharmaceuticals, Inc. Drug Profiles: - choriogonadotropin alfa - doxycycline - AZD-4901 - ESN-364 - GnRH Antagonists - metformin hydrochloride - Drugs to Inhibit GnRH Receptor for Dermatology, Hormonal Disorders, Non Malignant Disorders, Oncology and Women Health - Kisspeptin Peptide Antagonists - Metabolic Syndrome Program - KISS-1R Antagonist For Polycystic Ovarian Syndrome - Drugs to Inhibit PAI-1 for Thromboembolic Disease, PCOS and Alopecia For more information visit http://www.researchandmarkets.com/research/43d5b3/polycystic
Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H1 2014: 79 Companies Profiled
M2 - Wed May 07, 12:21PM CDT
Research and Markets (http://www.researchandmarkets.com/research/2d32kc/type_1_diabetes) has announced the addition of the "Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Type 1 Diabetes (Juvenile Diabetes), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Type 1 Diabetes (Juvenile Diabetes) and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - Alcon, Inc. - Johnson & Johnson - Boehringer Ingelheim GmbH - Osiris Therapeutics, Inc. - Sanofi - AstraZeneca PLC - Eli Lilly and Company - Inovio Pharmaceuticals, Inc. - MedImmune, LLC - Daiichi Sankyo Company, Limited - Merck & Co., Inc. - AbGenomics International, Inc. - Novo Nordisk A/S - Generex Biotechnology Corporation - BioLineRx, Ltd. - Kissei Pharmaceutical Co., Ltd. - Pfizer Inc. - Cell Therapeutics, Inc. - Hadasit Medical Research Services & Development Ltd - Biodel Inc. - MannKind Corporation - Halozyme Therapeutics, Inc. - Merck KGaA - Evotec AG - Karo Bio AB - Ligand Pharmaceuticals, Inc. - Opexa Therapeutics, Inc. - Compugen Ltd. - Oramed Pharmaceuticals, Inc. - Lexicon Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/2d...1_diabetes
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H1 2014: 23 Companies and 33 Drugs Profiled
M2 - Wed May 07, 12:10PM CDT
Research and Markets (http://www.researchandmarkets.com/research/p7dbhq/relapsing) has announced the addition of the "Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS) and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Companies Involved in Therapeutics Development - AbbVie Inc. - Actelion Ltd - Allozyne, Inc. - Amarna Therapeutics B.V. - Biogen Idec Inc. - Cognosci, Inc. - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. - Genmab A/S - GlaxoSmithKline plc - MedImmune, LLC - Merck KGaA - Mitsubishi Tanabe Pharma Corporation - Neurotec Pharma SL - Novartis AG - Nuron Biotech, Inc. - Opexa Therapeutics, Inc. - Receptos, Inc. - RedHill Biopharma Ltd. - Synthetic Biologics, Inc. - Teva Pharmaceutical Industries Limited - Trophos SA - XenoPort, Inc. Drug Profiles: - laquinimod sodium - dimethyl fumarate - laquinimod sodium - fingolimod hydrochloride - ocrelizumab - interferon beta-1b - daclizumab - RPC-1063 - Epigallocatechin Gallate - GSK-239512 - siponimod - tabalumab - firategrast - ponesimod - plovamer acetate - estriol - imilecleucel-t - olesoxime - ofatumumab - RNS-60 - (rifabutin clarithromycin clofazimine) - diazoxide - MT-1303 - Boswellic Acids - VAY-736 - MEDI-551 - interferon beta-1b pegylated - XP-23829 - Pegylated Interferon-Beta-1b - COG-133 For more information visit http://www.researchandmarkets.com/research/p7dbhq/relapsing
Women Infertility - Pipeline Review, H1 2014: 17 Company and 34 Drug Profiles
M2 - Wed May 07, 8:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wfm23g/women_infertility) has announced the addition of the "Women Infertility - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Women Infertility, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Women Infertility and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by our team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Involved in Therapeutics Development: - ASKA Pharmaceutical Co., Ltd. - Access Pharmaceuticals, Inc. - Actavis plc - AlphaMab Co., Ltd - Dong-A Socio Holdings Co Ltd - Ferring Pharmaceuticals, Inc. - Finox AG - Glycotope GmbH - Hanmi Pharmaceuticals, Co. Ltd. - IBSA Institut Biochimique SA - Isifer AB - Merck & Co., Inc. - Merck KGaA - Pantec Biosolutions AG - PregLem SA - Reliance Life Sciences Pvt. Ltd. - Teva Pharmaceutical Industries Limited - Trophogen, Inc. - Zydus Cadila Healthcare Limited Drug Profiles - corifollitropin alfa - follitropin alfa biosimilar - DR-2011 - choriogonadotropin alfa biosimilar - progesterone - RTPR-013 - follitropin alfa biosimilar - follitropin alfa biosimilar - follitropin delta - Isifera - FSH-GEX - menotropins - nimodipine - kisspeptin - filgrastim - triptorelin - progesterone Vaginal Gel Second Generation - AKP-501 - PGL-1001 - Prod-4 - Oral Fertility Drugs - HM-12160B - Follicle Stimulating Hormone Analog - Luteinizing Hormone Analog - KN-015 - Drugs to Inhibit GnRH Receptor for Dermatology, Hormonal Disorders, Non Malignant Disorders, Oncology and Women Health - follitropin alfa biosimilar - choriogonadotropin alfa biosimilar - Drugs for Female Infertility - FSH Agonist for Infertility For more information visit http://www.researchandmarkets.com/research/wf...nfertility
Bayer to buy Merck consumer business for $14.2B
By LINDA A. JOHNSON - AP - Tue May 06, 4:07PM CDT
TRENTON, N.J. (AP) — Germany's Bayer plans to buy U.S.-based Merck & Co.'s consumer health business, creating a combined medicine cabinet of household names from Bayer's aspirin to Merck's Claritin allergy pills.
Merck Wins Chinese Approval for AZ Electronics Takeover
at The Street - Thu May 01, 8:24AM CDT
China's Ministry of Commerce imposes conditions on the $3.1 billion deal.
Merck KGaA: Form 8 (DD) - AZ Electronic Materials S.A.
Marketwire - Wed Apr 30, 5:31AM CDT
Merck KGaA (FRANKFURT: MRK)
Global Cell Analysis Market 2014-2019: Instruments (Flow Cytometer, Microscope, Microfluidics, QPCR) & Application (Cell ID, Cell Viability, Cell Proliferation, Cytology, Signal Transduction, Single Cell)
M2 - Mon Apr 28, 9:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8bcf6h/cell_analysis) has announced the addition of the "Global Cell Analysis Market 2014-2019: Instruments (Flow Cytometer, Microscope, Microfluidics, QPCR), Consumables & Application (Cell Identification, Cell Viability, Cell Proliferation, Cytology, Signal Transduction, Single Cell Analysis)" report to their offering. In the recent years, the adoption of Cell Analysis for Cell identification, single cell analysis, cell proliferation, cell signaling, cell viability, cell signaling/transduction pathway, cell counting and quality control, cell structure study, and cell interaction, has increased. The market is broadly classified based on products, applications, end users, and geographies. The products market is further divided into instruments and consumables. The instruments market is sub-divided into cell counting instruments, microscopy, flow cytometry, high content screening, spectrophotometery, microfluidics, qRT-PCR, and cell microarrays. The consumables market is further segmented into reagents and assay kits, microplates, and other consumables. The applications market includes cell identification, cell interaction, cell viability, cell proliferation, cell structure studies, cell signaling pathway/signal transduction, cell counting and quality control, target identification, and validation and single cell analysis. Cell identification has its application in the identification of blood cells on the basis of their size and other morphological features such as presence or absence of nucleus in the cell and shape of nucleus. Cell identification is also used in tumor cell identification with the help of Raman spectroscopy and microfluidics. In target identification, HCS is used to identify novel targets through the screening of cellular pathways. HCS can also provide more accurate information about drug toxicity and mode of actions, which helps in further decision making and in driving the progress of drug discovery. Cell signalling pathways are used for the analysis of signalling pathways in drug discovery and therapeutic development, to differentiate drug resistant patterns in cancerous cells. The major factors driving the growth of the market are the rising incidence of cancer, corporate and government funding for cell-based research activities, rising incidence of chronic and infectious diseases, introduction of enhanced informatics solutions and improvements in image analysis products, and growing healthcare and medical spending. Moreover, the adoption of cell analysis for cell identification and cell signaling pathways/signal transduction pathways is the key growth opportunity in this market. Scope Instruments - Flow Cytometer - Microscope - Microfluidics - QPCR Consumables Application - Cell Identification - Cell Viability - Cell Proliferation - Cytology - Signal Transduction - Single Cell Analysis The report provides insights on the following pointers: - Market Penetration: Comprehensive information on the product portfolios and services offered by the top players in the cell analysis market. The report analyzes the cell analysis market by application across geographies. - Product Development/Innovation: Detailed insights on research and development activities and new product launches in the cell analysis market. - Market Development: Comprehensive information about the lucrative emerging markets. The report analyzes promising applications of the cell analysis market by product across geographies. - Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the cell analysis market. - Competitive Assessment: In-depth assessment of strategies, products and services, and distribution networks in the cell analysis market. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Market Overview 4 Global Cell Analysis Market, By Product Type 5 Products Market 6 Global Cell Analysis Market, By End Users 7 Geographic Analysis 8 Competitive Landscape 9 Company Profiles - Agilent Technologies, Inc. - Beckton, Dickinson and Company - Danaher Corporation - GE Healthcare - Merck KGAA - Olympus Corpopration - Perkinelmer, Inc. - Promega Corporation - Sigma-Aldrich Corporation - Thermo Fisher Scientific, Inc. For more information visit http://www.researchandmarkets.com/research/8b...l_analysis
Global Leishmaniasis (Kala-Azar) Therapeutics Pipeline Review 2014 - Analysis of 10 Companies & 30 Drug Profiles
M2 - Mon Apr 28, 5:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pr5bk6/leishmaniasis) has announced the addition of the "Leishmaniasis (Kala-Azar) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Leishmaniasis (Kala-Azar), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Leishmaniasis (Kala-Azar) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Leishmaniasis (Kala-Azar) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Leishmaniasis (Kala-Azar) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Leishmaniasis (Kala-Azar) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Involved in Therapeutics Development - Sanofi - Takeda Pharmaceutical Company Limited - Photopharmica Limited - Merck KGaA - iCo Therapeutics Inc. - Mologen AG - Advinus Therapeutics Ltd. - Dafra Pharma International Ltd. - aRigen Pharmaceuticals, Inc. - PolyTherics Limited Drug Profiles - pentoxifylline - fexinidazole - LEISH-F3 Vaccine - amphotericin B - MGN-1331 - Oleylphosphocholine - AS-605240 - Vaccine For Leishmania - amphotericin B NanoDisk - Small Molecules for Infectious Diseases - Small Molecule For Cutaneous Leishmaniasis - Small Molecule for Leishmaniasis - S-010269 - Compound-2d - VL-2098 - Compound-26g - pegylated amphotericin B - amphotericin b - Small Molecules For Leishmaniasis And Malaria - Isoxazole Containing Heteroretinoid And Amide Derivatives - Drug for Parasitic Diseases - Neglected Disease Program 2 - Small Molecules for Leishmaniasis and Oncology - methoxycoronaridine - Small Molecules to Inhibit HDAC for Oncology and Infectious Diseases - CDRI-99/288 - Nitroimidazole Backup Compound - Drug to Inhibit PDE for Leishmaniasis and Trypanosomiasis - Transfollicular Leishmaniasis Nanovaccine - ARA-03 For more information visit http://www.researchandmarkets.com/research/pr...shmaniasis
EMD Serono Presents New Data on Rebif® (interferon beta-1a) and Advancing MS Pipeline at AAN Annual Meeting
PR Newswire - Fri Apr 25, 8:00AM CDT
EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, announced today that new data from the company's multiple sclerosis (MS) portfolio will be presented at the American Academy of Neurology's 66th Annual Meeting, taking place from April 26 - May 3, in Philadelphia, PA.
BlackBerry CEO May Consider Exiting Handset Business; Celgene Corporation Favored over Natco in Pre-trial
ACCESSWIRE - Wed Apr 09, 11:43PM CDT
Merck & Co. Inc. (NYSE: MRK) - For an in-depth report on Merck & Co. Inc. follow: www.BullTrends.com/stockquote/MRK
Oncothyreon Announces Merck KGaA, Darmstadt, Germany, Initiation of Phase 3 START2 Study with Tecemotide in Stage III Non-Small Cell Lung Cancer
PR Newswire - Mon Apr 07, 5:00AM CDT
Oncothyreon Inc. (NASDAQ: ONTY) today announced that Merck KGaA, Darmstadt, Germany, has initiated the international Phase 3 START2 study, which is designed to assess the efficacy and safety of the investigational MUC1 antigen-specific cancer immunotherapy tecemotide (also known as L-BLP25) in patients with unresectable, locally advanced Stage III non-small cell lung cancer (NSCLC). Merck KGaA, Darmstadt, Germany, is developing tecemotide under a license agreement with Oncothyreon.
EMD Serono Announces Initiation of Phase III START2 Study with Tecemotide in Stage III Non-Small Cell Lung Cancer
CNW Group - Mon Apr 07, 1:20AM CDT
EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, today announced the initiation of the international Phase III START2 study, which is designed to assess the efficacy and safety of its investigational MUC1 antigen-specific cancer immunotherapy tecemotide (also known as L-BLP25) in patients with unresectable, locally advanced Stage III non-small cell lung cancer (NSCLC).
